Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E29.27 EPS (ttm)1.71 Insider Own0.10% Shs Outstand1.68B Perf Week0.50%
Market Cap84.14B Forward P/E17.19 EPS next Y2.91 Insider Trans-20.25% Shs Float1.50B Perf Month-10.73%
Income2.87B PEG1.73 EPS next Q0.65 Inst Own74.20% Short Float0.94% Perf Quarter-33.34%
Sales17.62B P/S4.78 EPS this Y-22.30% Inst Trans0.12% Short Ratio1.00 Perf Half Y-28.31%
Book/sh8.93 P/B5.60 EPS next Y10.69% ROA9.00% Target Price64.90 Perf Year-18.94%
Cash/sh2.76 P/C18.09 EPS next 5Y16.91% ROE19.60% 52W Range49.10 - 76.59 Perf YTD-25.96%
Dividend1.52 P/FCF- EPS past 5Y-12.20% ROI4.60% 52W High-34.69% Beta0.89
Dividend %3.04% Quick Ratio1.40 Sales past 5Y-3.20% Gross Margin75.70% 52W Low1.87% ATR1.05
Employees25000 Current Ratio1.60 Sales Q/Q17.00% Oper. Margin20.80% RSI (14)33.42 Volatility1.36% 1.72%
OptionableYes Debt/Eq0.45 EPS Q/Q990.60% Profit Margin16.30% Rel Volume0.61 Prev Close50.36
ShortableYes LT Debt/Eq0.44 EarningsOct 27 BMO Payout87.80% Avg Volume14.04M Price50.02
Recom2.50 SMA20-4.88% SMA50-9.60% SMA200-22.17% Volume8,554,117 Change-0.68%
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Jul-25-14Reiterated MKM Partners Sell $29 → $34
Oct-23-16 11:19AM  Its All About Positive Earnings Leverage
10:35AM  Top Health Care Earnings Coming Next Week at 24/7 Wall St.
Oct-21-16 02:19PM  U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients With Advanced Form of Bladder Cancer Business Wire
11:36AM  Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments
11:04AM  How Did Johnson & Johnsons Pharmaceutical Segment Do in 3Q16?
11:03AM  Bristol-Myers Squibb Updates Conference Call Dial-in/ID for Third Quarter 2016 Results on October 27 Business Wire
10:05AM  A Look at Johnson & Johnsons Segment-Wise Performance in 3Q16
09:44AM  Will Merck Report Another Healthy Quarter?
09:26AM  Bristol-Myers Squibb (BMY) Q3 Earnings: What's in Store?
Oct-19-16 02:10PM  Bristol-Myers Squibb Co. : BMY-US: Dividend Analysis : October 07th, 2016 (record date) : By the numbers : October 19, 2016
12:23PM  3 Reasons Bristol-Myers Is a Buy at Motley Fool
08:06AM  Eli Lillys 3Q16 Estimates: Expect Revenue Growth!
Oct-18-16 05:33PM  Roche's lung cancer drug wins U.S. approval Reuters
Oct-17-16 07:00PM  Cramer Remix: The video game space is on fire. Heres how...
04:04PM  Nike, Bristol-Myers Drop into Mondays 52-Week Low Club at 24/7 Wall St.
01:49PM  The Time Is Right to Pick Up Bristol-Myers Squibb
12:15PM  Bristol-Myers Squibb Foundation Joins White House Cancer Moonshot Business Wire
09:30AM  The Zacks Analyst Blog Highlights: Mylan, Pfizer, Roche, Merck and Bristol-Myers
08:44AM  Bristol-Myers Wins CHMP Nod for Opdivo Label Expansion
08:36AM  Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis at Motley Fool
Oct-16-16 12:56PM  High Pressure Economy Means Future-Focused Investing
Oct-15-16 07:04AM  3 Incredibly Cheap Big Pharma Stocks at Motley Fool
Oct-14-16 06:59AM  Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedot Business Wire
Oct-13-16 07:01PM  Bristol-Myers Asked to Seek Special Coverage for Opdivo in U.K. at Bloomberg
05:03PM  5 Dividend Stocks to Put on Your Shopping List at Motley Fool
02:59PM  Bristol-Myers (BMY) Stock Removed From Goldman's 'Conviction Buy' List
11:02AM  3 Value Stocks Near 52-Week Lows Worth Buying at Motley Fool
Oct-12-16 10:04AM  BMYs Drug Treatments That Go beyond Immuno-Oncology
08:04AM  How Large of a Role Does Opdivo Play in Bristol-Myers Squibbs Success?
07:00AM  3 Additions to the Wide Moat Focus Index at Morningstar
Oct-11-16 11:04AM  BMY Waiting to Enter the First-Line Lung Cancer Space
10:06AM  How Bristol-Myers Squibb Is Expanding Its Lung Cancer Treatments
08:05AM  Bristol-Myers Squibbs Strategies to Dominate Immuno-Oncology Market
07:03AM  How a Merck cancer breakthrough caused Bristol-Myers stock to plunge at MarketWatch
07:00AM  Trader's Daily Notebook: No One Wants to Take the Lead
12:13AM  [$$] An Extended Trial for Bristol-Myers Squibb at The Wall Street Journal
Oct-10-16 10:17PM  [$$] An Extended Trial for Bristol-MyersSquibb at The Wall Street Journal -10.14%
09:09PM  Bristol-Myers Partner Ono Drops as Cancer Drug Data Disappoint at Bloomberg
06:42PM  Why Bristol-Myers Squibb, Myriad Genetics, and Twilio Slumped Today at Motley Fool
06:21PM  Stocks Rise As Oil Rallies; Apple Up Amid Samsung Mess, Merck Pops
04:14PM  CheckMate Again for Bristol-Myers Squibb Co. As Shares Dip 10% at Motley Fool
04:04PM  Bristol-Myers, Staples Fall into Mondays 52-Week Low Club at 24/7 Wall St.
02:10PM  Analyst: Three things are pushing Mylan higher
02:07PM  Mylan soars on EpiPen settlement
01:52PM  Heres Why Bristol-Myers Squibb Co (BMY), Telefonica Brasil SA (ADR) (VIV) and Three Other Stocks Plunged on Monday at Insider Monkey
01:14PM  Bristol-Myers: The Worst Case Scenario? This is It. at
12:35PM  War on cancer
12:00PM  Bristol-Myers Squibb's Lost Ground
11:25AM  Mondays 3 Major Biopharma Movers at 24/7 Wall St.
11:04AM  Keytruda Leads over Opdivo in Head and Neck Cancer Treatment
11:04AM  Whats Driving Gileads Liver Disease Drug Portfolio?
10:56AM  This Wasn't A Great ESMO For Bristol-Myers Squibb, But 2017 Could Be A Much Better Year
10:28AM  Dow, S&P 500 Retake 50-Day Line; Merck Rallies On Cancer Drug News
10:27AM  Why Bristol-Myers (BMY) Stock Is Falling Today
10:25AM  Bristol-Myers' Opdivo Vs. Merck's Keytruda In Front-Line Lung Treatment
10:24AM  Bristol-Myers shares fall 9% after cancer treatment disappoints at CNBC
10:18AM  [$$] Bristol-Myers shares tumble 10% on failed clinical trial at Financial Times
10:06AM  Doctors grapple with best use of potent new cancer drugs
09:48AM  A new kind of drug is working better than chemotherapy in some lung cancer patients
09:23AM  Bristol-Myers stock drops nearly 9% after Merck announces positive lung cancer drug results at MarketWatch
09:15AM  Blog Coverage Bristol Myers Announces Positive Results for Yervoy Accesswire
09:08AM  Blog Coverage Bristol Myers Announces Positive Results for Yervoy
08:04AM  How Much Could Bristol-Myers Gain in 2016 and 2017?
07:57AM  Bristol-Myers Drops as Lung-Cancer Drug Disappoints Again
Oct-09-16 11:00PM  Merck Tops as Lung Cancer Treatment Moves Past Chemotherapy at Bloomberg
03:30PM  Mindset Shifts Take Time
01:22PM  Bristol-Myers Lung-Cancer Drug Disappoints in Trial Analysis at Bloomberg
12:31PM  AstraZeneca, Rivals Take Aim at Lung Cancer Combo Therapies at Bloomberg
08:45AM  Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer Business Wire
08:00AM  A new kind of treatment is working better than chemotherapy in some lung cancer patients
07:30AM  Updated Results Presented for the Opdivo (nivolumab) and Yervoy (ipilimumab) Combination in Metastatic Renal Cell Carcinoma From Phase 1 Study Business Wire
07:00AM  Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress Business Wire
02:15AM  Opdivo (nivolumab) Stabilized Patient-reported Outcomes in Patients With Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck in Pivotal Phase 3 CheckMate -141 Study Business Wire
02:15AM  Mercks Drug Succeeds in Lung Cancer Test, Could Become Standard at Bloomberg
02:15AM  Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advanced Lung Cancer Business Wire
02:13AM  [$$] Bristol-Myers lung cancer drug fails to meet immunotherapy hopes at Financial Times
Oct-08-16 03:09AM  Results From CheckMate-275 Validate Further Study of Opdivo (nivolumab) in Patients With Advanced Form of Bladder Cancer Business Wire
02:15AM  Yervoy (ipilimumab) Improves Overall Survival in Fully Resected Stage III Melanoma Patients From Phase 3 Study Business Wire
Oct-07-16 04:23PM  Incyte Could Stoke M&A Fire On 'Deep And Durable' Melanoma Drug Results
04:21PM  Understanding the Recent Fall in Bristol-Myers Squibbs Valuation
12:22PM  6 Healthcare Stocks Investors Can't Miss in Q3 Earnings
09:30AM  The Zacks Analyst Blog Highlights: Costco, ExxonMobil, Bristol-Myers, Shire and Darden
Oct-06-16 05:52PM  Billions at stake for big pharma
07:24AM  4 Top Growth Stocks Priced at a Bargain This Fall at Motley Fool
Oct-05-16 02:52PM  Tune In Sunday For More On Bristol-Myers's Cancer Drug at
10:04AM  How Much Return Could Gilead Offer in the Next Year?
Oct-03-16 05:13PM  New Research From Bristol-Myers Squibb at ESMO 2016 Congress Reinforces Leadership in Immuno-Oncology and Differentiated Research Approach Business Wire
11:47AM  [$$] ConvaTec to Raise $1.8 Billion in London Float at The Wall Street Journal
05:54AM  3 Growth Dividend Stocks to Buy in October at Motley Fool
Oct-02-16 12:44PM  Passing Inflection Point on Pricing and Profits
Sep-30-16 07:04PM  Understanding Mercks Business Segments and Their Revenue Trends
09:41AM  ETFs with exposure to Bristol-Myers Squibb Co. : September 30, 2016
Sep-29-16 06:04PM  The Pfizer-Anacor Deal: A Review
11:51AM  52-Week Company Lows
11:21AM  Two Stocks Teach a Lesson About Losses
Sep-28-16 05:51PM  Bristol-Myers, Nektar Tie-Up for Opdivo/NKTR-214 Combo
04:04PM  Bristol-Myers, Abercrombie & Fitch Slide into Wednesdays 52-Week Low Club
04:01PM  Exxon, Chevron Dominate DJIA Wednesday
12:59PM  Top trades for the 2nd half: BMY, CRM & more
11:00AM  Bristol-Myers Squibb Slides Into Value-Stock Territory
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANDREOTTI LAMBERTODirectorOct 11Option Exercise17.51368,7066,456,042692,868Oct 13 05:00 PM
ANDREOTTI LAMBERTODirectorSep 08Sale56.9710,800615,276323,699Sep 09 04:41 PM
ANDREOTTI LAMBERTODirectorSep 07Sale56.7710,800613,116334,499Sep 09 04:41 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,596029,722Sep 07 04:33 PM
ANDREOTTI LAMBERTODirectorAug 25Sale58.9211,600683,472345,299Aug 25 05:10 PM
ANDREOTTI LAMBERTODirectorAug 24Sale59.4311,600689,359356,899Aug 25 05:10 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,511015,250Aug 03 04:56 PM
ANDREOTTI LAMBERTODirectorJul 08Sale75.0411,600870,461368,499Jul 11 05:12 PM
ANDREOTTI LAMBERTODirectorJul 07Sale73.8611,600856,776380,099Jul 11 05:12 PM
Blin EmmanuelSVP, Chief Strategy OfficerJul 02Option Exercise0.00951012,516Jul 06 05:58 PM
Gordon MurdoEVP, Chief Commercial OfficerJul 01Option Exercise0.002,335014,950Jul 06 05:58 PM
Cuss Francis MEVP & CSOJul 01Option Exercise0.003,6550291,628Jul 06 05:58 PM
ANDREOTTI LAMBERTODirectorJun 29Sale72.799,800713,342392,194Jun 30 05:42 PM
ANDREOTTI LAMBERTODirectorJun 28Sale71.6713,400960,396390,394Jun 30 05:42 PM
Elicker John ESVP, Public Affairs & IRJun 14Sale72.6911,820859,21955,011Jun 16 04:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMay 20Sale70.7930,2012,137,838184,694May 24 05:04 PM
Caldarella Joseph CSVP & ControllerMay 16Sale72.473,519255,00455,238May 17 04:46 PM
Caforio GiovanniChief Executive OfficerMay 05Option Exercise0.008,0400134,549May 09 04:42 PM
Caforio GiovanniChief Executive OfficerMay 03Option Exercise24.7950,4551,250,602145,958May 05 04:31 PM
Caforio GiovanniChief Executive OfficerMay 03Sale71.3134,5942,466,885117,118May 05 04:31 PM
ANDREOTTI LAMBERTODirectorMay 02Option Exercise26.04234,7206,112,787671,514May 04 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyMay 02Sale71.9522,2181,598,65221,971May 04 05:28 PM
ANDREOTTI LAMBERTODirectorMay 02Sale71.88234,72016,870,792436,794May 04 05:28 PM
ANDREOTTI LAMBERTODirectorApr 05Sale66.0011,600765,626436,794Apr 06 04:18 PM
ANDREOTTI LAMBERTODirectorApr 04Sale65.7911,600763,216448,394Apr 06 04:18 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554025,260Apr 05 04:59 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0031,624055,059Mar 14 09:44 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0037,1430300,492Mar 14 09:43 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00204,4470574,101Mar 14 09:43 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,860074,177Mar 14 09:43 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0020,460067,864Mar 14 09:44 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,406089,478Mar 14 09:42 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0060,6230132,906Mar 14 09:42 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0057,4840366,730Mar 14 09:42 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,435032,069Mar 14 09:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.008,806059,091Mar 14 09:41 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0075,6180247,158Mar 14 09:41 PM
Blin EmmanuelSVP, Head of CommercializationMar 10Option Exercise0.0011,707013,498Mar 14 09:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 10Option Exercise0.0019,309019,608Mar 14 09:41 PM
CAMPBELL LEWIS BDirectorMar 08Option Exercise24.962,50062,4002,500Mar 10 04:36 PM
CAMPBELL LEWIS BDirectorMar 08Sale66.002,500165,0000Mar 10 04:36 PM
Caforio GiovanniChief Executive OfficerMar 06Option Exercise0.002,889079,627Mar 08 04:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 06Option Exercise0.001,28202,611Mar 08 04:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724050,821Mar 08 04:43 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931048,253Mar 08 04:43 PM
LEUNG SANDRAEVP, General CounselMar 06Option Exercise0.005,5740315,121Mar 08 04:41 PM
Elicker John ESVP, Public Affairs & IRMar 06Option Exercise0.001,043053,715Mar 08 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100269,043Mar 08 04:42 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,391060,032Mar 08 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3240169,885Mar 08 04:40 PM
Blin EmmanuelSVP, Head of CommercializationMar 06Option Exercise0.0081901,553Mar 08 04:41 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528024,746Mar 08 04:40 PM
Caldarella Joseph CSVP & ControllerMar 04Sale64.6412,962837,91646,322Mar 07 05:41 PM
Caforio GiovanniChief Executive OfficerFeb 17Option Exercise22.8920,125460,66188,778Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Option Exercise22.7314,560330,949319,699Feb 19 04:32 PM
Caforio GiovanniChief Executive OfficerFeb 17Sale63.5812,040765,52776,738Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Sale63.5710,152645,342309,547Feb 19 04:32 PM
ANDREOTTI LAMBERTODirectorFeb 04Option Exercise0.00148,1800445,820Feb 08 04:31 PM
Paliwal Dinesh CDirectorFeb 01Option Exercise0.003,25703,257Feb 03 06:28 PM
ANDREOTTI LAMBERTODirectorJan 05Sale68.1911,600791,028310,424Jan 06 04:40 PM
ANDREOTTI LAMBERTODirectorJan 04Sale66.9311,600776,332322,024Jan 06 04:40 PM
Elicker John ESVP Pub Affairs & Inv RelationJan 03Option Exercise0.00950053,012Jan 05 06:21 PM
ANDREOTTI LAMBERTODirectorDec 15Sale70.0511,600812,580332,852Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorDec 14Sale68.0011,600788,843344,452Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorNov 20Sale67.7611,600786,016501,052Nov 23 04:41 PM
ANDREOTTI LAMBERTODirectorNov 19Sale67.0211,600777,470512,652Nov 23 04:41 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000163,957Nov 03 03:45 PM
Elicker John ESVP Pub Affairs & Inv RelationNov 01Option Exercise0.00496052,286Nov 03 03:45 PM